CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation
Newsmakers
CytoDyn (OTC: CYDY) First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19
The Company’s Phase 2b/3 trial is for patients with severe and critically ill COVID-19 indications. Interim analysis will be conducted after results for first 50 patients are available. VANCOUVER, Washington, Apr 15, 2020 — CytoDyn […]
Healthcare
CytoDyn (OTC: CYDY) Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test
Dr. Richard Pestell, who leads CytoDyn’s cancer, NASH and GvHD programs, recently named to The Order of Australia, established by Queen Elizabeth II VANCOUVER, Washington, June 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]
Healthcare
CytoDyn (OTC: CYDY) to Present at RHK Capital 2019 Disruptive Growth Conference
VANCOUVER, Washington, Aug. 29, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]